January 2, 2019
Novacap becomes SEQENS
Novacap announced last month that all its activities would unify their names to become SEQENS.
"As SEQENS, we intend to stand as a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our mission is to bring R&D and industrial performance to our clients' projects. From now on, we want to better leverage on our strong expertise to develop and produce highly complex molecules with unique skills and the largest continuum of technologies available on the market," says Pierre Luzeau, SEQENS CEO.
More information can be found on www.seqens.com